SCHEMBL2106429

SCHEMBL2106429

O=C(O)[C@@H]1C[C@@H](S(=O)(=O)c2ccc(F)cc2F)CN1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.38
AKR1C3 P42330 1/20 0.37
HTT P42858 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
SLC1A3 P43003 1/20 0.36
SLC1A2 P43004 1/20 0.36
SLC1A1 P43005 1/20 0.36
GRIK1 P39086 4/20 0.35
GRIA2 P42262 4/20 0.35
TBXA2R P21731 2/20 0.35
AKR1B1 P15121 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
KCNH2 Q12809 1/20 0.35
POLB P06746 1/20 0.33
DPP4 P27487 1/20 0.33
FAP Q12884 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL696063 0.87 AKR1B1 (0.40) CTSSAKR1C3GRIK1GRIA2AKR1B1
SCHEMBL3077827 0.85 CTSS (0.48) CTSSCYP1A2CYP2D6ALOX15CYP2C19
SCHEMBL695316 0.79 CTSS (0.66) CTSS
Hydrochloric Acid SCHEMBL696606 0.78 CTSS (0.65) CTSS
SCHEMBL2107430 0.76 GRIK1 (0.40) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
SCHEMBL2105653 0.76 GRIK1 (0.41) CYP1A2CYP2D6ALOX15CYP2C19SLC1A3
SCHEMBL695605 0.74 CTSS (0.37) CTSSAKR1C3AKR1B1
SCHEMBL2663826 0.74 KCNH2 (0.43) TBXA2RAKR1B1HTR2AHTR2CKCNH2
SCHEMBL15170415 0.74 MEN1 (0.38) CTSSHTTCYP1A2CYP2D6ALOX15
SCHEMBL2106278 0.74 GRIK1 (0.39) CTSSGRIK1GRIA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP claimed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US claimed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 CTSS 1542/4885AKR1C3 567/4885HTT 2701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.